Quick Answer
Definium Therapeutics, Inc. reported Earnings Per Share Diluted of $2.06 (loss) per share for the year ending 2025.
- Definium Therapeutics, Inc. showed a decrease of -33.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Definium Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.11 (loss) per share | Q3 2021: $0.61 (loss) per share | Q1 2022: $0.66 (loss) per share | Q2 2022: $0.60 (loss) per share | Q3 2022: $0.56 (loss) per share | Q1 2023: $0.65 (loss) per share | Q2 2023: $0.76 (loss) per share | Q3 2023: $0.45 (loss) per share | Q1 2024: $1.14 (loss) per share | Q2 2024: $0.26 (loss) per share | Q3 2024: $0.27 (loss) per share | Q1 2025: $0.35 (loss) per share | Q2 2025: $0.50 (loss) per share | Q3 2025: $0.78 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Definium Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 39.4%.
- Historical annual values: Fiscal year 2025: $2.06 (loss) per share | Fiscal year 2024: $1.54 (loss) per share | Fiscal year 2023: $2.44 (loss) per share | Fiscal year 2022: $1.84 (loss) per share | Fiscal year 2021: $3.40 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: